ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Trump’s Tariffs Could Make Drugs and Devices More Expensive


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

USA China trade war tariffs

It’s not just soup cans and car parts that stand to be affected by President Trump’s proposed tariffs on Chinese goods. Prescription drugs and medical devices also are on the list of goods that may have 25 percent tariffs placed on them.

If the tariffs aren’t averted, they’re sure to push already-high drug and medical device prices to new levels.

As usual, bad things tend to flow down. And at the bottom of this particular pecking order are sick people. Medical patients are likely to pay the price if this possible trade war erupts into a new kind of drug war.

China is a major provider of prescription drug ingredients in the U.S.

Drug Ingredients on Tariff List

Included on the president’s proposed tariff list are vaccines, malaria diagnostic test kits, epinephrine, prostaglandins, L-thyroxine (levothyroxine) and dozens of medicaments, or substances used for medical treatment. There are also sterile surgical suture materials, tissue adhesives for wound closing, dental cements and fillings.

The targets include ingredients for drugs, including insulin, as well as blood products and antidepressants.

The Association for Accessible Medicines, which represents generic and biosimilar drug manufacturers, issued a statement suggesting the proposed tariff list of pharmaceutical ingredients and products might have an effect on costs: “We are concerned that the proposed tariffs may lead to increased costs of manufacturing for generics and biosimilars and thus higher prescription drug prices for patients in the U.S.

“For an administration that wants to lower drug prices, this would do the exact opposite,” said Ben Wakana, executive director of Patients For Affordable Drugs, in a statement to Drugwatch. “We are eager to read the comprehensive set of recommendations the administration promised to release in the next few weeks, but the tariffs announced (recently) would be a step in the wrong direction. It’s a tax that would raise prices on prescription drugs.”

Medical Device Industry Faces Losses

Tariffs could also affect pacemakers, artificial joints, defibrillators and birth control pills, according to the New York Times.  Medtronic and Zimmer Biomet have orthopedic device factories in China, which export to the U.S. One estimate says that if the proposed 25 percent tariff takes effect, the medical device industry could lose up to $1.5 billion annually.

Those costs would likely be passed on to consumers.

From about 2001 to 2016, most of China’s medical device exports were low tech, according to a recent report in the U.S. International Trade Commission Journal of International Commerce and Economics. But that has shifted toward more medium and high-tech devices.

The report credits two factors for this change: China’s vast and expanding health care market and government policies that have emphasized production of innovative devices by local companies.

Orthopedic implantable devices comprised one of the fastest-growing Chinese exports, according to the report, increasing by 189 percent between 2011 to 2016. Also, diagnostic equipment exports, including MRIs and electrocardiographs, grew 37 percent.

The report also says these Chinese products tend to be less expensive than those made elsewhere. “Chinese-produced devices can retail at anywhere from 10 to 70 percent of the price of multinational firms, depending on the product,” the report states.

Elaine Silvestrini
Written By Elaine Silvestrini Writer

Elaine Silvestrini is an award-winning journalist with 30 years of experience covering state and federal court systems. She joined Drugwatch in 2017. Her coverage for Drugwatch has been cited in the CDC’s Public Health Law News and the USA Today Network. Some of her qualifications include:

  • Centers for Disease Control and Prevention certificates in Health Literacy
  • Experience as an assistant investigator for the Federal Public Defender
  • Loyola Law School Journalist Law School Fellowship
Edited By

6 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Association for Accessible Medicines. (2018, April 4). AAM Statement on China Tariffs. Retrieved from
  2. Thomas, K. and Kaplan, S. (2018, April 7). Why Trump’s tariffs could raise the cost of a hip replacement. Retrieved from
  3. Langreth, R. and Edney, A. (2018, April 3). Trump Tariffs Target Key Ingredients for Dozens of Drugs. Retrieved
  4. Office of the United States Trade Representative. (2018, April). List of products and intended tariff increases. Retrieved
  5. Torsekar, M.P. (2018, January). China’s Changing Medical Device Exports. Retrieved
  6. Langreth, R. and Edney, A. (2018, April 3). Trump Tariffs Target Key Ingredients for Dozens of Drugs. Retrieved
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617